Exane Derivatives’s Orthofix Medical OFIX Stock Holding History

Exane Derivatives’s Portfolio OFIX Stock Details OFIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,395	Closed	-$73.9K	–	702
2019 Q3	$73.9K	Hold	1,395	–	–	0.01%	343
2019 Q2	$73.7K	Hold	1,395	–	–	0.01%	360
2019 Q1	$78.7K	Buy	1,395 +672	+93%	+$37.7K	0.02%	320
2018 Q4	$37.9K	Buy	+723	New	+$41.1K	0.01%	389

Other funds holding OFIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $8.43B AUM 52.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Exane Derivatives's OFIX Position: Q4 2019 in Review

Exane Derivatives sold out of Orthofix Medical (OFIX) in Q4 2019, closing a stake of 1,395 shares — an estimated $73.9K sold.

Exane Derivatives first reported a position in OFIX in Q4 2018 and held it in 4 quarters. The position peaked at $78.7K in Q1 2019. 157 funds tracked by Wall St. Rank hold OFIX as of Q4 2019.

Exane Derivatives reported no remaining Orthofix Medical position as of Q4 2019 after selling out during the quarter.
Exane Derivatives sold 1,395 Orthofix Medical shares in Q4 2019, an estimated $73.9K.
Exane Derivatives first reported a position in Orthofix Medical in Q4 2018 and held it in 4 quarters.
Exane Derivatives's Orthofix Medical position peaked at $78.7K in Q1 2019.
157 funds tracked by Wall St. Rank held Orthofix Medical as of Q4 2019.

Based on Exane Derivatives's 13F filing for Q4 2019, filed 22 Jan 2020.